Description
| Description | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2]. |
| In vitro | Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2]. |
| In vivo | Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice[2]. Animal Model: CB-17/SCID mice (6 weeks) were injected with OVA10 cells[2] |
| Molecular Weight |
N/A |
| Formula | N/A |
| CAS No. | 1018448-65-1 |
Storage
store at -20 ℃
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
